Renal Cell Carcinoma – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, H1 2012', provides an overview of the Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. 'Renal Cell Carcinoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
- A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Renal Cell Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Renal Cell Carcinoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Renal Cell Carcinoma 12
Renal Cell Carcinoma Therapeutics under Development by Companies 14
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Renal Cell Carcinoma Therapeutics – Products under Development by Companies 32
Renal Cell Carcinoma Therapeutics – Products under Investigation by Universities/Institutes 38
Companies Involved in Renal Cell Carcinoma Therapeutics Development 49
Bristol-Myers Squibb Company 49
Genzyme Corporation 50
Boehringer Ingelheim GmbH 51
F. Hoffmann-La Roche Ltd. 52
Kyowa Hakko Kirin Co., Ltd. 53
Amgen Inc. 54
AstraZeneca PLC 55
Eli Lilly and Company 56
GlaxoSmithKline plc 57
Seattle Genetics, Inc. 58
Genentech, Inc. 59
Emergent BioSolutions Inc. 60
Oxford BioMedica plc 61
Novartis AG 62
ImClone Systems Incorporated 63
Astellas Pharma Inc. 64
Eisai Co., Ltd. 65
Ono Pharmaceutical Co., Ltd. 66
OSI Pharmaceuticals, Inc. 67
Pfizer Inc. 68
Taiho Pharmaceutical Co., Ltd. 69
Exelixis, Inc. 70
Celgene Corporation 71
Bayer AG 72
MannKind Corporation 73
3SBio Inc. 74
EntreMed, Inc. 75
Celldex Therapeutics, Inc. 76
Active Biotech AB 77
Lorus Therapeutics Inc 78
Bionomics Limited 79
Northwest Biotherapeutics, Inc. 80
Cleveland BioLabs, Inc. 81
Flamel Technologies S.A. 82
Dendreon Corporation 83
MOLOGEN AG 84
OncoTherapy Science, Inc. 85
Threshold Pharmaceuticals, Inc. 86
Rexahn Pharmaceuticals, Inc. 87
Antisense Pharma GmbH 88
Wilex AG 89
Philogen S.p.A. 90
immatics biotechnologies GmbH 91
Curacyte AG 92
Argos Therapeutics, Inc. 93
Cytheris SA 94
AgrenVec, S.L. 95
MacroGenics, Inc. 96
Pivotal BioSciences, Inc. 97
Jennerex Biotherapeutics, Inc. 98
Endocyte, Inc. 99
Advenchen Laboratories, LLC 100
Immutep S.A. 101
Syndax Pharmaceuticals, Inc. 102
Tigris Pharmaceuticals, Inc. 103
AVEO Pharmaceuticals, Inc. 104
Advanced Cancer Therapeutics 105
Renal Cell Carcinoma – Therapeutics Assessment 106
Assessment by Monotherapy Products 106
Assessment by Combination Products 107
Assessment by Route of Administration 108
Assessment by Molecule Type 110
Drug Profiles 113
Axitinib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Axitinib - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Sutent - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
ANYARA - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
IMA901 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
TroVax - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
NuLeusin - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Tivozanib - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Rencarex - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Dovitinib - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Aldesleukin for Kidney Cancer - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Bevacizumab + Torisel - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Interferon Alfa-2B + Bevacizumab - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Interferon Alfa-2B - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Sunitinib - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Interferon Alfa + CCI-779 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
TroVax + IL-2 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Interferon-Alpha - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Everolimus + Bevacizumab - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
ANYARA + Interferon Alpha - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Sunitinib - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Interferon-alpha - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Interleukin 2 + Interferon-alpha2 - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Sorafenib - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Sorafenib + Sunitinib - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Recombinant Gamma Interferon - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Bevacizumab + Interferon Alfa-2a - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
Renal Cell Carcinoma Therapeutics – Drug Profile Updates 148
Renal Cell Carcinoma Therapeutics – Discontinued Products 154
Renal Cell Carcinoma Therapeutics - Dormant Products 156
Renal Cell Carcinoma – Product Development Milestones 168
Featured News & Press Releases 168
Jan 03, 2012: AVEO And Astellas Announce Positive Phase III Trial Results Of Tivozanid In Comparision With Sorafenib For Treatmant Of Renal Cell Cancer 168
Dec 07, 2011: FDA Advisory Committee Finds Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma To Be Favorable 169
Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule 169
Nov 21, 2011: IDMC Recommends Conducting Final Analysis Of Pivotal Phase III Trial With WILEX's RENCAREX 170
Nov 03, 2011: AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses 171
Oct 05, 2011: FDA Grants Fast Track Designation To WILEX’s RENCAREX For Adjuvant Therapy Of Clear Cell Renal Cell Carcinoma 172
Sep 13, 2011: Pfizer To Present Clinical Data On Axitinib Portfolio At 2011 European Multidisciplinary Cancer Congress 172
Sep 13, 2011: Bayer And Onyx Announce Presentation Of New Nexavar Data At 2011 ECCO-ESMO Congress 173
Sep 13, 2011: Bayer To Present New Data On Regorafenib At 2011 ECCO-ESMO Congress 174
Sep 13, 2011: Pfizer To Present Clinical Data On SUTENT At 2011 European Multidisciplinary Cancer Congress 174
Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 177
Contact Us 177
Disclaimer 177
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Renal Cell Carcinoma, H1 2012 12
Products under Development for Renal Cell Carcinoma – Comparative Analysis, H1 2012 13
Number of Products under Development by Companies, H1 2012 15
Number of Products under Development by Companies, H1 2012 (Contd..1) 16
Number of Products under Development by Companies, H1 2012 (Contd..2) 17
Number of Products under Development by Companies, H1 2012 (Contd..3) 18
Number of Products under Development by Companies, H1 2012 (Contd..4) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 26
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 27
Comparative Analysis by Late Stage Development, H1 2012 28
Comparative Analysis by Mid Clinical Stage Development, H1 2012 29
Comparative Analysis by Early Clinical Stage Development, H1 2012 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 31
Products under Development by Companies, H1 2012 32
Products under Development by Companies, H1 2012 (Contd..1) 33
Products under Development by Companies, H1 2012 (Contd..2) 34
Products under Development by Companies, H1 2012 (Contd..3) 35
Products under Development by Companies, H1 2012 (Contd..4) 36
Products under Development by Companies, H1 2012 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2012 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 48
Bristol-Myers Squibb Company, H1 2012 49
Genzyme Corporation, H1 2012 50
Boehringer Ingelheim GmbH, H1 2012 51
F. Hoffmann-La Roche Ltd., H1 2012 52
Kyowa Hakko Kirin Co., Ltd., H1 2012 53
Amgen Inc., H1 2012 54
AstraZeneca PLC, H1 2012 55
Eli Lilly and Company, H1 2012 56
GlaxoSmithKline plc, H1 2012 57
Seattle Genetics, Inc., H1 2012 58
Genentech, Inc., H1 2012 59
Emergent BioSolutions Inc., H1 2012 60
Oxford BioMedica plc, H1 2012 61
Novartis AG, H1 2012 62
ImClone Systems Incorporated, H1 2012 63
Astellas Pharma Inc., H1 2012 64
Eisai Co., Ltd., H1 2012 65
Ono Pharmaceutical Co., Ltd., H1 2012 66
OSI Pharmaceuticals, Inc., H1 2012 67
Pfizer Inc., H1 2012 68
Taiho Pharmaceutical Co., Ltd., H1 2012 69
Exelixis, Inc., H1 2012 70
Celgene Corporation, H1 2012 71
Bayer AG, H1 2012 72
MannKind Corporation, H1 2012 73
3SBio Inc., H1 2012 74
EntreMed, Inc., H1 2012 75
Celldex Therapeutics, Inc., H1 2012 76
Active Biotech AB, H1 2012 77
Lorus Therapeutics Inc, H1 2012 78
Bionomics Limited, H1 2012 79
Northwest Biotherapeutics, Inc., H1 2012 80
Cleveland BioLabs, Inc., H1 2012 81
Flamel Technologies S.A., H1 2012 82
Dendreon Corporation, H1 2012 83
MOLOGEN AG, H1 2012 84
OncoTherapy Science, Inc., H1 2012 85
Threshold Pharmaceuticals, Inc., H1 2012 86
Rexahn Pharmaceuticals, Inc., H1 2012 87
Antisense Pharma GmbH, H1 2012 88
Wilex AG, H1 2012 89
Philogen S.p.A., H1 2012 90
immatics biotechnologies GmbH, H1 2012 91
Curacyte AG, H1 2012 92
Argos Therapeutics, Inc., H1 2012 93
Cytheris SA, H1 2012 94
AgrenVec, S.L., H1 2012 95
MacroGenics, Inc., H1 2012 96
Pivotal BioSciences, Inc., H1 2012 97
Jennerex Biotherapeutics, Inc., H1 2012 98
Endocyte, Inc., H1 2012 99
Advenchen Laboratories, LLC, H1 2012 100
Immutep S.A., H1 2012 101
Syndax Pharmaceuticals, Inc., H1 2012 102
Tigris Pharmaceuticals, Inc., H1 2012 103
AVEO Pharmaceuticals, Inc., H1 2012 104
Advanced Cancer Therapeutics, H1 2012 105
Assessment by Monotherapy Products, H1 2012 106
Assessment by Combination Products, H1 2012 107
Assessment by Stage and Route of Administration, H1 2012 109
Assessment by Molecule Type, H1 2012 112
Renal Cell Carcinoma Therapeutics – Drug Profile Updates 148
Renal Cell Carcinoma Therapeutics – Discontinued Products 154
Renal Cell Carcinoma Therapeutics – Discontinued Products (Contd..1) 155
Renal Cell Carcinoma Therapeutics – Dormant Products 156
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..1) 157
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..2) 158
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..3) 159
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..4) 160
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..5) 161
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..6) 162
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..7) 163
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..8) 164
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..9) 165
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..10) 166
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..11) 167
List of Figures
Number of Products under Development for Renal Cell Carcinoma, H1 2012 12
Products under Development for Renal Cell Carcinoma – Comparative Analysis, H1 2012 13
Products under Development by Companies, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 20
Late Stage Products, H1 2012 28
Mid Clinical Stage Products, H1 2012 29
Early Clinical Stage Products, H1 2012 30
Discovery and Pre-Clinical Stage Products, H1 2012 31
Assessment by Monotherapy Products, H1 2012 106
Assessment by Combination Products, H1 2012 107
Assessment by Route of Administration, H1 2012 108
Assessment by Stage and Route of Administration, H1 2012 109
Assessment by Molecule Type, H1 2012 110
Assessment by Stage and Molecule Type, H1 2012 111
[Tabellenverzeichnis ausblenden]